Medicinal Chemistry of Quinazolines as Anticancer Agents Targeting Tyrosine Kinases

被引：32

作者：

Zayed, Mohamed F. F. ^{[1
,2
]}

机构：

[1] Fakeeh Coll Med Sci, Pharmaceut Sci Dept, Jeddah 21461, Saudi Arabia

[2] Al Azhar Univ, Fac Pharm, Pharmaceut Chem Dept, Cairo 11884, Egypt

来源：

SCIENTIA PHARMACEUTICA | 2023年 / 91卷 / 02期

关键词：

quinazoline; development; discovery; design; synthesis; anticancer; structure activity relationship; POTENT EGFR INHIBITORS; CYCLIN-DEPENDENT KINASE; ENHANCED ANTIPROLIFERATIVE ACTIVITIES; AURORA-B KINASE; BIOLOGICAL EVALUATION; IN-VITRO; 4-ANILINOQUINAZOLINE DERIVATIVES; PHOSPHATIDYLINOSITOL; 3-KINASE; SELECTIVE INHIBITORS; DIOXYGENATED RINGS;

D O I：

10.3390/scipharm91020018

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cancer is a large group of diseases that can affect any organ or body tissue due to the abnormal cellular growth with the unknown reasons. Many of the existing chemotherapeutic agents are highly toxic with a low level of selectivity. Additionally, they lead to development of therapeutic resistance. Hence, the development of targeted chemotherapeutic agents with low side effects and high selectivity is required for cancer treatment. Quinazoline is a vital scaffold well-known to be linked with several biological activities. The anticancer activity is one of the prominent biological activities of this scaffold. Several established anticancer quinazolines work by different mechanisms on the various molecular targets. The aim of this review is to present different features of medicinal chemistry as drug design, structure activity relationship, and mode of action of some targeted anticancer quinazoline derivatives. It gives comprehensive attention on the chemotherapeutic activity of quinazolines in the viewpoint of drug discovery and its development. This review provides panoramic view to the medicinal chemists for supporting their efforts to design and synthesize novel quinazolines as targeted chemotherapeutic agents.

引用

页数：34

共 110 条

[1] Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase [J].